Indivior Pharmaceuticals, Inc. (DELISTED) (INDV:DL)
36.28
+0.91
(+2.57%)
USD |
NASDAQ |
Nov 02, 16:00
Indivior Pharmaceuticals Net Income (Quarterly) : 137.00M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 137.00M |
| June 30, 2026 | 122.00M |
| March 31, 2026 | 89.00M |
| December 31, 2025 | 102.00M |
| September 30, 2025 | 42.00M |
| June 30, 2025 | 18.00M |
| March 31, 2025 | 47.00M |
| December 31, 2024 | 21.00M |
| September 30, 2024 | 22.00M |
| June 30, 2024 | -97.00M |
| March 31, 2024 | 61.00M |
| December 31, 2023 | 54.00M |
| September 30, 2023 | -135.00M |
| June 30, 2023 | 39.00M |
| March 31, 2023 | 44.00M |
| December 31, 2022 | -183.00M |
| September 30, 2022 | 41.00M |
| June 30, 2022 | 48.00M |
| March 31, 2022 | 41.00M |
| December 31, 2021 | 35.00M |
| September 30, 2021 | 27.00M |
| June 30, 2021 | 62.00M |
| March 31, 2021 | 80.00M |
| December 31, 2020 | -13.00M |
| Date | Value |
|---|---|
| September 30, 2020 | 10.00M |
| June 30, 2020 | 18.00M |
| March 31, 2020 | -163.00M |
| December 31, 2019 | -55.00M |
| September 30, 2019 | 48.00M |
| June 30, 2019 | 75.00M |
| March 31, 2019 | 66.00M |
| December 31, 2018 | 24.00M |
| September 30, 2018 | 89.00M |
| June 30, 2018 | 70.00M |
| March 31, 2018 | 93.00M |
| December 31, 2017 | -145.00M |
| September 30, 2017 | 50.00M |
| June 30, 2017 | 73.00M |
| March 31, 2017 | 80.00M |
| December 31, 2016 | 78.00M |
| September 30, 2016 | -149.00M |
| June 30, 2016 | 57.00M |
| March 31, 2016 | 50.00M |
| December 31, 2015 | 37.00M |
| September 30, 2015 | 48.00M |
| June 30, 2015 | 66.00M |
| March 31, 2015 | 77.00M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Supernus Pharmaceuticals, Inc. | 20.91M |
| Bristol Myers Squibb Co. | 2.162B |
| Eli Lilly & Co. | 6.451B |
| Ligand Pharmaceuticals, Inc. | -28.48M |
| Amneal Pharmaceuticals, Inc. | 12.31M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 356.00M |
| Total Expenses (Quarterly) | 219.00M |
| EPS Diluted (Quarterly) | 1.123 |
| Enterprise Value | 4.477B |
| Gross Profit Margin (Quarterly) | 85.67% |
| Profit Margin (Quarterly) | 38.48% |
| Earnings Yield | 9.96% |
| Operating Earnings Yield | 13.65% |
| Normalized Earnings Yield | 11.29 |